NCT01138033 - Study of a Focal Adhesion Kinase Inhibitor in Subjects With Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 27, 2010

Primary Completion Date

December 21, 2015

Study Completion Date

December 21, 2015

Conditions

Cancer

Interventions

DRUG

GSK2256098

GSK2256098 is a potent focal adhesion kinase inhibitor that will be administered orally as 20, 100 or 250 mg capsules. The starting dose in Part 1 is 80 mg twice daily. The dose will continue to be increased until the maximum tolerated dose is identified.

Trial Locations (10)

3084

GSK Investigational Site, Heidelberg

6009

GSK Investigational Site, Nedlands

14033

GSK Investigational Site, Caen

94805

GSK Investigational Site, Villejuif

G61 1BD

GSK Investigational Site, Glasgow

NW1 2BU

GSK Investigational Site, London

W12 0HS

GSK Investigational Site, London

W1G 6AD

GSK Investigational Site, London

M20 4BX

GSK Investigational Site, Manchester

NE7 7DN

GSK Investigational Site, Newcastle upon Tyne